Latest news with #MorganLuttrell
Associated Press
21-05-2025
- Health
- Associated Press
IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 20, 2025 ( NEWMEDIAWIRE ) - Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans - a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he's pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell is helping lead legislative efforts to fund clinical trials through the VA and Pentagon, despite resistance from some conservatives and recent regulatory setbacks like the FDA's rejection of an MDMA therapy from Lykos Therapeutics. Amid this shift, NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary HOPE Therapeutics are emerging as leaders in veteran-focused psychedelic innovation. HOPE is developing ketamine-based treatments for acute suicidality and major depression and is building a nationwide network of… Read More NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on
News.com.au
17-05-2025
- Politics
- News.com.au
GOP Lawmaker on His Life-Altering Psychedelic Trip
Rep. Morgan Luttrell opens up about his psychedelic experience in Mexico, where he took ibogaine, a drug that is illegal in the U.S.
Wall Street Journal
17-05-2025
- Politics
- Wall Street Journal
GOP Lawmaker on His Life-Altering Psychedelic Trip
Rep. Morgan Luttrell opens up about his psychedelic experience in Mexico, where he took ibogaine, a drug that is illegal in the U.S. Photo: Umit Gulsen
Yahoo
17-05-2025
- Politics
- Yahoo
GOP Lawmaker on His Life-Altering Psychedelic Trip
Rep. Morgan Luttrell opens up about his psychedelic experience in Mexico, where he took ibogaine, a drug that is illegal in the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
17-05-2025
- Health
- Wall Street Journal
Lawmaker ‘Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It
Morgan Luttrell says he had never smoked anything, let alone tried drugs in his life. So the retired Navy SEAL had to ask a nearby nurse for guidance on how to inhale a psychedelic drug that was part of the final step of an intense three-day experimental therapy. Luttrell had traveled to Mexico in 2018 to take ibogaine, a drug that is illegal in the U.S. but is gaining a reputation within the veteran community as a potential treatment to address complicated conditions like post-traumatic stress disorder. Inhaling a separate drug, called DMT, was the final step in the process.
